Biovail Continues Fight to Protect Wellbutrin XL (SeekingAlpha via Yahoo! Finance)
David Harper submits: Last August, the U.S. District Court for the Central District of California granted summary judgment of noninfringment to Anchen Pharmaceuticals in its case against Biovail over generic Wellbutrin XL.

FDA looks to increase user fees for drugmakers (The Star-Ledger)
WASHINGTON -- The Food and Drug Administration yesterday proposed a 29 percent boost in the yearly user fees paid by the pharmaceutical industry to help improve drug safety oversight, speed new drug approvals and monitor direct-to-consumer television advertising.

FDA: Pay To Be Watched (Forbes)
The government wants Big Pharma companies to pay to have the safety of their drugs monitored.